DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma.
about
Receptor binding peptides for target-selective delivery of nanoparticles encapsulated drugsTherapeutic enhancement of protective immunity during experimental leishmaniasisImmunosuppressive networks in the tumour environment and their therapeutic relevanceTrends in immunoconjugate and ligand-receptor based targeting development for cancer therapy.The role of regulatory T cells in cancer.A novel transferrin receptor-targeted hybrid peptide disintegrates cancer cell membrane to induce rapid killing of cancer cells.Depleting syndecan-4+ T lymphocytes using toxin-bearing dendritic cell-associated heparan sulfate proteoglycan-dependent integrin ligand: a new opportunity for treating activated T cell-driven diseaseTregs and rethinking cancer immunotherapy.Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytesInability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma.Denileukin diftitox: a novel immunotoxin.Mechanism of diphtheria toxin catalytic domain delivery to the eukaryotic cell cytosol and the cellular factors that directly participate in the process.Potential antitumor therapeutic application of Grimontia hollisae thermostable direct hemolysin mutantsImmunosuppressive tumor microenvironment in cervical cancer patientsPartial reduction of human FOXP3+ CD4 T cells in vivo after CD25-directed recombinant immunotoxin administrationNanoparticle-aptamer bioconjugates for cancer targeting.Tumor-stromal interactions in pancreatic cancerHow to detour Treg cells in T cell-based antitumor immune therapy.Targeted toxins in brain tumor therapy.T-cell tolerance in cancer.Targeting T cell immunometabolism for cancer immunotherapy; understanding the impact of the tumor microenvironment.Immunogenicity and toxicity of transferrin receptor-targeted hybrid peptide as a potent anticancer agent.Clinical targeting recombinant immunotoxins for cancer therapyInfluence of tumors on protective anti-tumor immunity and the effects of irradiation.Prophylactic DNA vaccine targeting Foxp3(+) regulatory T cells depletes myeloid-derived suppressor cells and improves anti-melanoma immune responses in a murine model.Engineering toxins for 21st century therapies.Potent anti-tumor responses to immunization with dendritic cells loaded with tumor tissue and an NKT cell ligand.Natural products as reservoirs of novel therapeutic agents.Leveraging Physiology for Precision Drug Delivery
P2860
Q26849241-92E0062E-196F-48EC-8FB5-75D3D09242E3Q28476803-63D9348C-6CBA-4BDD-934C-C085845250F6Q29619244-5A70D842-783A-44DC-A793-2CBE49695888Q33311571-80CAD575-F84A-4896-8C0F-80569C68A710Q33631986-089250C4-8153-459C-81F5-58E30354B1C3Q33995305-668279B4-41B2-4752-8EC7-7C9DC10024E2Q34235950-B5132D79-D91D-4B94-B5FC-EF9FB2143791Q34625147-01AC879A-C049-44B7-9939-F4258E8CB843Q34664957-36EB8E2C-CC72-4F2B-90CB-43D7354FC963Q34943798-35B2F4DF-5305-4BC3-95D5-2BD216E412C9Q35007337-11028487-3B5B-4316-B377-A1AA12607080Q35458800-542E7DE9-4664-4040-90BB-B9038983F3F1Q35538464-DFEB77A3-25ED-421C-ACCA-EB49B9B6DCC8Q35603131-763740C2-6A40-4CA6-A4DC-C01CB27BC03EQ36344582-74F54C6B-1529-45F2-A9E7-8182ACE964DEQ36460842-8FDD1344-F5F1-41B5-96B0-3960EE9A3A3DQ36784603-ED140C40-A2DE-4A7B-A550-B090DDA0F16EQ37169964-C792C10E-CC41-496E-ABEA-E24ABEA8469EQ37954275-3FDA4EA1-6A9C-4864-A77E-5C29AFF69564Q38103582-B75E1E14-1CC4-40A2-B0A7-783E068C2D07Q38218127-43759637-3184-43E6-98FD-0A13EF8BF378Q39208816-86114A84-ACC0-4380-8474-A95A184ACABAQ41149227-0D048821-FCA3-47AE-8A3B-5E6A1E2B88EEQ42945799-EA9EC120-F329-4EB4-9DCF-B74DBB83C43EQ46264331-920EA0D6-351B-4D76-949B-08F7D98C0096Q51724514-26F32C0F-8F91-481B-8192-AED7B27E6D58Q54278437-D2309454-DDE6-4167-9BE6-0FA87048E248Q55217571-54A8DDEE-039C-42B3-A93C-52AC938E3B8BQ57428850-B9E4A00B-FFB4-4C0C-9873-D1000F012F7E
P2860
DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma.
description
2000 nî lūn-bûn
@nan
2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
DAB
@nl
DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma.
@ast
DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma.
@en
type
label
DAB
@nl
DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma.
@ast
DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma.
@en
prefLabel
DAB
@nl
DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma.
@ast
DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma.
@en
P356
P1476
DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma.
@en
P2093
P304
110-6; discussion 117
P356
10.3816/CLM.2000.N.009
P577
2000-09-01T00:00:00Z